ナノマテリアルベースアジュバントワクチンのグローバル市場 2021年：企業別、地域別、種類・用途別

• 英文タイトル：Global Nanomaterial-Based Adjuvants Vaccine Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-203B16250 • 出版社/出版日：GlobalInfoResearch / 2021年12月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

ナノマテリアルベースアジュバントワクチン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のナノマテリアルベースアジュバントワクチンの市場規模は2020年のxxx米ドルから2021年にはxxx米ドルと推定され、2020年から2021年の間にxxx％の変化があります。世界のナノマテリアルベースアジュバントワクチンの市場規模は次の5年間でxxx％のCAGRで成長すると予想されます。 ナノマテリアルベースアジュバントワクチン市場は種類と用途によって区分されます。2016年～2026年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・水酸化アルミニウム、リン酸アルミニウム、リポソーム、その他 用途別セグメントは次のように区分されます。 ・肺炎球菌、ヒトパピローマウイルス、Dtap、A型肝炎、B型肝炎、コロナウイルス、その他 世界のナノマテリアルベースアジュバントワクチン市場の主要な市場プレーヤーは以下のとおりです。 ・Emergent BioSolutions、Sanofi、GlaxoSmithKline Biologicals、Merck、Pfizer、Novartis、Moderna 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計14章あります。 ・第1章では、ナノマテリアルベースアジュバントワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なナノマテリアルベースアジュバントワクチンメーカーの企業概要、2019年～2021年までのナノマテリアルベースアジュバントワクチンの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なナノマテリアルベースアジュバントワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2016年～2026年までの地域別ナノマテリアルベースアジュバントワクチンの販売量、売上、成長性を示しています。 ・第5、6章では、2016年～2026年までのナノマテリアルベースアジュバントワクチンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2016年～2021年までの世界の主要国での販売量、売上、市場シェア、並びに2021年～2026年までの主要地域でのナノマテリアルベースアジュバントワクチン市場予測を収録しています。 ・第12、13、14章では、ナノマテリアルベースアジュバントワクチンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Emergent BioSolutions、Sanofi、GlaxoSmithKline Biologicals、Merck、Pfizer、Novartis、Moderna ・メーカー別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：水酸化アルミニウム、リン酸アルミニウム、リポソーム、その他 ・用途別分析2016年-2026年：肺炎球菌、ヒトパピローマウイルス、Dtap、A型肝炎、B型肝炎、コロナウイルス、その他 ・ナノマテリアルベースアジュバントワクチンの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ナノマテリアルベースアジュバントワクチンのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ナノマテリアルベースアジュバントワクチンのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ナノマテリアルベースアジュバントワクチンの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ナノマテリアルベースアジュバントワクチンの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Nanomaterial-Based Adjuvants Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Nanomaterial-Based Adjuvants Vaccine size is estimated to be million in 2021 from USD million in 2020, with a change of % between 2020 and 2021. The global Nanomaterial-Based Adjuvants Vaccine market size is expected to grow at a CAGR of % for the next five years.

Market segmentation
Nanomaterial-Based Adjuvants Vaccine market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Aluminum Hydroxide
Aluminum Phosphate
Liposomes
Other

Market segment by Application can be divided into
Pneumococcus
Human Papilloma Virus
Dtap
Hepatitis A
Hepatitis B
Coronavirus
Other

The key market players for global Nanomaterial-Based Adjuvants Vaccine market are listed below:
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Nanomaterial-Based Adjuvants Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Nanomaterial-Based Adjuvants Vaccine, with price, sales, revenue and global market share of Nanomaterial-Based Adjuvants Vaccine from 2019 to 2021.
Chapter 3, the Nanomaterial-Based Adjuvants Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Nanomaterial-Based Adjuvants Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Nanomaterial-Based Adjuvants Vaccine market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Nanomaterial-Based Adjuvants Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Nanomaterial-Based Adjuvants Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Aluminum Hydroxide
1.2.3 Aluminum Phosphate
1.2.4 Liposomes
1.2.5 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Pneumococcus
1.3.3 Human Papilloma Virus
1.3.4 Dtap
1.3.5 Hepatitis A
1.3.6 Hepatitis B
1.3.7 Coronavirus
1.3.8 Other
1.4 Global Nanomaterial-Based Adjuvants Vaccine Market Size & Forecast
1.4.1 Global Nanomaterial-Based Adjuvants Vaccine Sales in Value (2016-2026))
1.4.2 Global Nanomaterial-Based Adjuvants Vaccine Sales in Volume (2016-2026)
1.4.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2016-2026) & (US$/Unit)
1.5 Global Nanomaterial-Based Adjuvants Vaccine Production Capacity Analysis
1.5.1 Global Nanomaterial-Based Adjuvants Vaccine Total Production Capacity (2016-2026)
1.5.2 Global Nanomaterial-Based Adjuvants Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Nanomaterial-Based Adjuvants Vaccine Market Drivers
1.6.2 Nanomaterial-Based Adjuvants Vaccine Market Restraints
1.6.3 Nanomaterial-Based Adjuvants Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 Emergent BioSolutions
2.1.1 Emergent BioSolutions Details
2.1.2 Emergent BioSolutions Major Business
2.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product and Services
2.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Product and Services
2.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 GlaxoSmithKline Biologicals
2.3.1 GlaxoSmithKline Biologicals Details
2.3.2 GlaxoSmithKline Biologicals Major Business
2.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product and Services
2.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Product and Services
2.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Product and Services
2.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Product and Services
2.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Moderna
2.7.1 Moderna Details
2.7.2 Moderna Major Business
2.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Product and Services
2.7.4 Moderna Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Nanomaterial-Based Adjuvants Vaccine Sales by Manufacturer
3.1 Global Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Nanomaterial-Based Adjuvants Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Nanomaterial-Based Adjuvants Vaccine Manufacturer Market Share
3.4.2 Top 6 Nanomaterial-Based Adjuvants Vaccine Manufacturer Market Share
3.5 Global Nanomaterial-Based Adjuvants Vaccine Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Nanomaterial-Based Adjuvants Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region
4.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Region (2016-2026)
4.1.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2016-2026)
4.2 North America Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026)
4.3 Europe Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026)
4.4 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026)
4.5 South America Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026)
4.6 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Type (2016-2026)
5.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2016-2026)
5.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Application (2016-2026)
6.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2016-2026)
6.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2026)
7.2 North America Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2026)
7.3 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country
7.3.1 North America Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Country (2016-2026)
7.3.2 North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2026)
8.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2026)
8.3 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country
8.3.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Country (2016-2026)
8.3.2 Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2026)
9.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2026)
9.3 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Region
9.3.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2026)
10.2 South America Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2026)
10.3 South America Nanomaterial-Based Adjuvants Vaccine Market Size by Country
10.3.1 South America Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Country (2016-2026)
10.3.2 South America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2026)
11.2 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2026)
11.3 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country
11.3.1 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Nanomaterial-Based Adjuvants Vaccine Typical Distributors
12.3 Nanomaterial-Based Adjuvants Vaccine Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type, (USD Million), 2021-2026
Table 2. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application, (USD Million), 2021-2026
Table 3. Emergent BioSolutions Basic Information, Manufacturing Base and Competitors
Table 4. Emergent BioSolutions Major Business
Table 5. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product and Services
Table 6. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Sanofi Basic Information, Manufacturing Base and Competitors
Table 8. Sanofi Major Business
Table 9. Sanofi Nanomaterial-Based Adjuvants Vaccine Product and Services
Table 10. Sanofi Nanomaterial-Based Adjuvants Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. GlaxoSmithKline Biologicals Basic Information, Manufacturing Base and Competitors
Table 12. GlaxoSmithKline Biologicals Major Business
Table 13. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product and Services
Table 14. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Merck Basic Information, Manufacturing Base and Competitors
Table 16. Merck Major Business
Table 17. Merck Nanomaterial-Based Adjuvants Vaccine Product and Services
Table 18. Merck Nanomaterial-Based Adjuvants Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Major Business
Table 21. Pfizer Nanomaterial-Based Adjuvants Vaccine Product and Services
Table 22. Pfizer Nanomaterial-Based Adjuvants Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Novartis Basic Information, Manufacturing Base and Competitors
Table 24. Novartis Major Business
Table 25. Novartis Nanomaterial-Based Adjuvants Vaccine Product and Services
Table 26. Novartis Nanomaterial-Based Adjuvants Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Moderna Basic Information, Manufacturing Base and Competitors
Table 28. Moderna Major Business
Table 29. Moderna Nanomaterial-Based Adjuvants Vaccine Product and Services
Table 30. Moderna Nanomaterial-Based Adjuvants Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Global Nanomaterial-Based Adjuvants Vaccine Sales by Manufacturer (2019-2021e) & (K Units)
Table 32. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 33. Market Position of Manufacturers in Nanomaterial-Based Adjuvants Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 34. Global Nanomaterial-Based Adjuvants Vaccine Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Nanomaterial-Based Adjuvants Vaccine Production Site of Key Manufacturer
Table 36. Nanomaterial-Based Adjuvants Vaccine New Entrant and Capacity Expansion Plans
Table 37. Nanomaterial-Based Adjuvants Vaccine Mergers & Acquisitions in the Past Five Years
Table 38. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2016-2021e) & (K Units)
Table 39. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2021-2026) & (K Units)
Table 40. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2016-2021e) & (USD Million)
Table 41. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2021-2026) & (USD Million)
Table 42. Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2021e) & (K Units)
Table 43. Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021-2026) & (K Units)
Table 44. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2016-2021e) & (USD Million)
Table 45. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2021-2026) & (USD Million)
Table 46. Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2016-2021e) & (US$/Unit)
Table 47. Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2021-2026) & (US$/Unit)
Table 48. Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2021e) & (K Units)
Table 49. Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021-2026) & (K Units)
Table 50. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2016-2021e) & (USD Million)
Table 51. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2021-2026) & (USD Million)
Table 52. Global Nanomaterial-Based Adjuvants Vaccine Price by Application (2016-2021e) & (US$/Unit)
Table 53. Global Nanomaterial-Based Adjuvants Vaccine Price by Application (2021-2026) & (US$/Unit)
Table 54. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2016-2021e) & (K Units)
Table 55. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2026) & (K Units)
Table 56. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2016-2021e) & (USD Million)
Table 57. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 58. North America Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2021e) & (K Units)
Table 59. North America Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021-2026) & (K Units)
Table 60. North America Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2021e) & (K Units)
Table 61. North America Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021-2026) & (K Units)
Table 62. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2016-2021e) & (K Units)
Table 63. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2026) & (K Units)
Table 64. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2016-2021e) & (USD Million)
Table 65. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 66. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2021e) & (K Units)
Table 67. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021-2026) & (K Units)
Table 68. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2021e) & (K Units)
Table 69. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021-2026) & (K Units)
Table 70. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2016-2021e) & (K Units)
Table 71. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2021-2026) & (K Units)
Table 72. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2016-2021e) & (USD Million)
Table 73. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2021-2026) & (USD Million)
Table 74. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2021e) & (K Units)
Table 75. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021-2026) & (K Units)
Table 76. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2021e) & (K Units)
Table 77. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021-2026) & (K Units)
Table 78. South America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2016-2021e) & (K Units)
Table 79. South America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2026) & (K Units)
Table 80. South America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2016-2021e) & (USD Million)
Table 81. South America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 82. South America Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2021e) & (K Units)
Table 83. South America Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021-2026) & (K Units)
Table 84. South America Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2021e) & (K Units)
Table 85. South America Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021-2026) & (K Units)
Table 86. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2016-2021e) & (K Units)
Table 87. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2026) & (K Units)
Table 88. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2016-2021e) & (USD Million)
Table 89. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 90. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Type (2016-2021e) & (K Units)
Table 91. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021-2026) & (K Units)
Table 92. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Application (2016-2021e) & (K Units)
Table 93. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021-2026) & (K Units)
Table 94. Direct Channel Pros & Cons
Table 95. Indirect Channel Pros & Cons
Table 96. Nanomaterial-Based Adjuvants Vaccine Typical Distributors
Table 97. Nanomaterial-Based Adjuvants Vaccine Typical Customers
List of Figures
Figure 1. Nanomaterial-Based Adjuvants Vaccine Picture
Figure 2. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type in 2020
Figure 3. Aluminum Hydroxide
Figure 4. Aluminum Phosphate
Figure 5. Liposomes
Figure 6. Other
Figure 7. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application in 2020
Figure 8. Pneumococcus
Figure 9. Human Papilloma Virus
Figure 10. Dtap
Figure 11. Hepatitis A
Figure 12. Hepatitis B
Figure 13. Coronavirus
Figure 14. Other
Figure 15. Global Nanomaterial-Based Adjuvants Vaccine Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 16. Global Nanomaterial-Based Adjuvants Vaccine Market Size and Forecast (2016-2026) & (USD Million)
Figure 17. Global Nanomaterial-Based Adjuvants Vaccine Sales (2016-2026) & (K Units)
Figure 18. Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2016-2026) & (US$/Unit)
Figure 19. Global Nanomaterial-Based Adjuvants Vaccine Production Capacity (2016-2026) & (K Units)
Figure 20. Global Nanomaterial-Based Adjuvants Vaccine Production Capacity by Geographic Region: 2020 VS 2021
Figure 21. Nanomaterial-Based Adjuvants Vaccine Market Drivers
Figure 22. Nanomaterial-Based Adjuvants Vaccine Market Restraints
Figure 23. Nanomaterial-Based Adjuvants Vaccine Market Trends
Figure 24. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturer in 2020
Figure 25. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Manufacturer in 2020
Figure 26. Nanomaterial-Based Adjuvants Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. Top 3 Nanomaterial-Based Adjuvants Vaccine Manufacturer (Revenue) Market Share in 2020
Figure 28. Top 6 Nanomaterial-Based Adjuvants Vaccine Manufacturer (Revenue) Market Share in 2020
Figure 29. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2016-2026)
Figure 30. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2016-2026)
Figure 31. North America Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026) & (USD Million)
Figure 32. Europe Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026) & (USD Million)
Figure 33. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026) & (USD Million)
Figure 34. South America Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026) & (USD Million)
Figure 35. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue (2016-2026) & (USD Million)
Figure 36. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2016-2026)
Figure 37. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2016-2026)
Figure 38. Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2016-2026) & (US$/Unit)
Figure 39. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2016-2026)
Figure 40. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2016-2026)
Figure 41. Global Nanomaterial-Based Adjuvants Vaccine Price by Application (2016-2026) & (US$/Unit)
Figure 42. North America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2016-2026)
Figure 43. North America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2016-2026)
Figure 44. North America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2016-2026)
Figure 45. North America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2016-2026)
Figure 46. United States Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2016-2026)
Figure 50. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2016-2026)
Figure 51. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2016-2026)
Figure 52. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2016-2026)
Figure 53. Germany Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. France Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. United Kingdom Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Russia Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Italy Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2016-2026)
Figure 60. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2016-2026)
Figure 61. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2016-2026)
Figure 62. China Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Japan Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Korea Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. India Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Southeast Asia Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Australia Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2016-2026)
Figure 69. South America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2016-2026)
Figure 70. South America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2016-2026)
Figure 71. South America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2016-2026)
Figure 72. Brazil Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Argentina Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2016-2026)
Figure 75. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2016-2026)
Figure 76. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2016-2026)
Figure 77. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2016-2026)
Figure 78. Turkey Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Egypt Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Saudi Arabia Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. South Africa Nanomaterial-Based Adjuvants Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source

---